Literature DB >> 20138441

Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells.

Leena Strien1, Marjut Leidenius, Karl von Smitten, Päivi Heikkilä.   

Abstract

Our aim was to compare the HER-2 and hormone receptor status between primary tumor (PT) and sentinel node (SN) metastases in breast cancer. We analyzed 65 PTs with 42 macrometastases, 18 micrometastases, and 5 ITCs for the HER-2 amplification status and for the hormone receptor status. In HER-2-positive PTs, 26 of 29 metastases were HER-2-positive, including all six analyzed micrometastases and ITCs. Three macrometastases were HER-2-negative. In HER-2-negative PTs, 35 of 36 metastases were HER-2-negative. A low-grade HER-2 amplification was detected in one micrometastasis. A full concordance between the PT and SN metastases in both HER-2 amplification and ER and PR status was observed in 40 of 56 (71%) cases. These 40 fully concordant cases included 27 macrometastatic, 9 micrometastatic, and 4 ITC-cases. The concordance in HER-2, ER, and PR was high between the PT and their SN metastases. However, the concordance may be remarkably lower when analyzed simultaneously for all three predictive factors. Copyright 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138441     DOI: 10.1016/j.prp.2009.12.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.

Authors:  Vassiliki Kotoula; Konstantine T Kalogeras; George Kouvatseas; Despoina Televantou; Ralf Kronenwett; Ralph M Wirtz; George Fountzilas
Journal:  Virchows Arch       Date:  2012-12-20       Impact factor: 4.064

2.  Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis.

Authors:  Antonio Ieni; Valeria Barresi; Rosario Caltabiano; Alessia Caleo; Luca Reggiani Bonetti; Salvatore Lanzafame; Pio Zeppa; Rosario Alberto Caruso; Giovanni Tuccari
Journal:  Int J Mol Sci       Date:  2014-12-03       Impact factor: 5.923

3.  Cysts mark the early stage of metastatic tumor development in non-small cell lung cancer.

Authors:  Chitra Thakur; Ulf R Rapp; Thomas Rudel
Journal:  Oncotarget       Date:  2017-12-30

Review 4.  Detecting Tumor Metastases: The Road to Therapy Starts Here.

Authors:  M E Menezes; S K Das; I Minn; L Emdad; X-Y Wang; D Sarkar; M G Pomper; P B Fisher
Journal:  Adv Cancer Res       Date:  2016-08-17       Impact factor: 6.242

5.  Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.

Authors:  Li Peng; Zhen Zhang; Dachun Zhao; Jialin Zhao; Feng Mao; Qiang Sun
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

6.  ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.

Authors:  Kristiina Joensuu; Marjut Leidenius; Mia Kero; Leif C Andersson; Kathryn B Horwitz; Päivi Heikkilä
Journal:  Breast Cancer (Auckl)       Date:  2013-02-13

7.  St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.

Authors:  Anna-Karin Falck; Mårten Fernö; Pär-Ola Bendahl; Lisa Rydén
Journal:  BMC Cancer       Date:  2013-11-25       Impact factor: 4.430

8.  Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases.

Authors:  Li Peng; Zhen Zhang; Dachun Zhao; Jialin Zhao; Feng Mao; Qiang Sun
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.